Hubbry Logo
HaemoneticsHaemoneticsMain
Open search
Haemonetics
Community hub
Haemonetics
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Haemonetics
Haemonetics
Haemonetics
View on Wikipedia
from Wikipedia

Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.[2]

Key Information

Today, the company has expanded and has offices located in 16 countries. The company employs more than 1,800 people and markets its products in over 50 countries. Revenue is derived nearly equally from its three major markets -- Asia, Europe, and the Americas.

History

[edit]

The company was founded in 1971. Haemonetics started out producing the containers and bags required for blood collection. The Latham Bowl was a disposable container that could automate the separation of blood by centrifugation. Through the 90's, the company added additional product lines and technologies. The company opened a manufacturing facility in Holbrook, Massachusetts in 1988.[citation needed]

In 1995 the company purchased the Intravenous Solutions manufacturing facility in Union, South Carolina.[citation needed]

Additional acquisitions grew the company and expanded its services. In the following years the company branched off to making the whole plasma collection station including the machine, supplies and software for plasma collection. These acquisitions included Edmonton-based Fifth Dimension (5D) Information Systems to gain entry into the blood and plasma software industry.[citation needed] Further acquisitions include Chicago-based Arryx in July 2006,[3] Information Data Management, Inc. in January 2007,[4] the acquisition of a division of Haemoscope in 2007,[citation needed] the acquisition of Infonale in July 2007,[5] and, in 2009, Chico, California-based Altivation and Tucson, Arizona-based Sebra.[citation needed]

On August 21, 2007, 5D and IDM were officially merged into a new subsidiary called Haemonetics Software Solutions.[6] The employees at both Edmonton (5D) and Rosemont (IDM) continue to work from their respective offices.

Further acquisitions included the April 2009 acquisition of Neoteric Technology Ltd[7] and the April 2010 acquisition of California-based Global Med Technologies, Inc.[8] Haemonetics acquired the Pall Corporation's transfusion medicine business on August 1, 2012 for ~$550 million.[9]

In April 2024, it was announced Haemonetics had completed its acquisition of the Chicago-headquartered medical device temperature regulation manufacturer, Attune Medical for $160 million.[10]

Product categories

[edit]

Haemonetics products can be considered as belonging to two broad categories. Donor products (marketed to the blood donation industry, these include products that automate the blood donation process, automate the processing of blood, support pathogen inactivation and bacterial detection of blood, and test blood hematocrit); and products that are marketed to the surgical suite for blood loss management for patients. These products include surgical blood salvage (or "autotransfusion") devices, surgical field blood suction systems, and blood and patient warming systems.[citation needed]

Hemostasis

[edit]
  • TEG 5000
    • Kaolin TEG
    • Kaolin TEG with Heparinase
    • RapidTEG
    • TEG Functional Fibrinogen
    • TEG PlateletMapping
  • TEG 6S

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Haemonetics

View on Grokipedia
from Grokipedia
Haemonetics Corporation is a global medical technology company founded in 1971 and headquartered in , , that develops innovative solutions to enhance the quality, effectiveness, and efficiency of healthcare, with a primary focus on management, plasma collection, and technologies. The company operates in over 90 countries and serves hospitals, plasma centers, and centers through three main business segments: Plasma, which provides automated collection systems and software; Center, offering processing and pathogen reduction solutions; and , delivering transfusion management, testing, and surgical salvage technologies. Haemonetics was established by biomedical engineer Allan "Jack" Latham Jr., who invented the Latham Bowl in the late 1960s—a disposable, transparent bowl that automated the separation of from via continuous flow , marking a significant advancement over manual methods. The firm's first product, the V50 system incorporating the Latham Bowl, launched in 1972 and enabled safer, more efficient component collection for transfusion and pharmaceutical uses. Building on this innovation, Haemonetics introduced the Cell Saver autologous recovery system in 1974 to reduce the need for donor during surgeries, followed by expansions into international markets with its first overseas headquarters in the and the PCS2 plasma collection system in the 1990s. The company went public on the in 1979 and has since grown through strategic acquisitions, such as the 2023 purchase of OpSens Inc. for cardiovascular monitoring technologies and the 2024 acquisition of Attune Medical for devices, while divesting non-core assets like its product line in 2025. Today, Haemonetics' portfolio includes flagship products like the TEG 6s analyzer for rapid clotting assessments, BloodTrack software for secure transfusion tracking, and the Express Plus automated pleretic system for plasma donation, all designed to minimize blood waste, reduce transfusion risks, and support plasma collection centers worldwide with an installed base of over 2,500 automated devices. With net revenues of $1.36 billion in fiscal year 2025, the company emphasizes patient-centered innovation, corporate responsibility, and values such as integrity and continuous improvement to advance global healthcare standards.

Overview

Company Profile

Haemonetics Corporation was founded in by Allan "Jack" Latham Jr. in , initially focusing on the production of collection containers and automated separation technology. Today, Haemonetics is recognized as a global leader in medical technology for management, providing innovative solutions to hospitals, plasma collection centers, and banks worldwide for the collection, processing, and transfusion of and its components. The company is headquartered in , , having relocated its global headquarters there from Braintree in 2019, and employs approximately 3,023 personnel across its operations as of March 2025. Haemonetics operates through core business segments including plasma collection, hospital solutions, and blood center technologies, with an emphasis on advancing to enhance outcomes and in healthcare settings.

Mission and Values

Haemonetics' mission is to improve the quality, effectiveness, and efficiency of healthcare through innovative medical technology solutions focused on blood management. This commitment drives the company's efforts to advance patient care by enhancing clinical outcomes and supporting global blood supply chains. The company's core values include thinking big to foster innovation, taking action with proactive accountability, winning together through collaboration, acting with integrity in all decisions, committing to quality in operations, taking initiative to drive progress, and being accountable for results. These values are embedded in Haemonetics' corporate culture and guide daily practices across its global operations. Haemonetics demonstrates its quality commitments through adherence to stringent regulatory standards, including FDA regulations for s and ISO certifications such as ISO 27001 for . The company maintains a robust that ensures compliance with laws and ethical practices in medical device manufacturing, prioritizing and product reliability. Value-driven initiatives at Haemonetics include programs to promote diversity and inclusion, such as policies outlined in its that foster a collaborative and prohibit . Additionally, sustainability efforts are integrated into its environmental, social, and governance (ESG) framework, aligning with core values to responsibly grow the business while investing in people and social impact.

History

Founding and Early Innovations

Haemonetics was founded in 1971 by Allen "Jack" Latham Jr., a biomedical engineer from , who aimed to address longstanding inefficiencies in blood collection and separation amid rising demands for safer transfusions in medical practice. Latham, who had previously developed innovative blood processing concepts during his career at Harvard and other institutions, established the company in , to commercialize automated devices that could streamline the fractionation of into components like plasma, platelets, and red cells. Operations began in 1972 after securing $1 million in private funding from investors, following the termination of a marketing agreement with for an early prototype. This initial capital supported a heavy focus on (R&D) for disposable and automated technologies, enabling Haemonetics to navigate early financial constraints while prioritizing innovation in a nascent field. The company's inaugural product, the Model 10 blood processing machine, launched in the early and represented a breakthrough in automated for separating components using disposable Latham bowls—a patented that minimized risks compared to manual methods. Sold primarily to banks and hospitals, the Model 10 automated the and deglycerolization of frozen red cells, significantly reducing processing time and labor while improving component purity. Haemonetics complemented this hardware with the development of disposable collection bags and containers, which became essential for hygienic, single-use applications in . These early offerings addressed critical inefficiencies in handling, driven by R&D investments that emphasized and in response to expanding surgical and therapeutic needs. A pivotal advancement came in 1974 with the introduction of the Cell Saver system, the first commercially viable device for , which collected, washed, and reinfused autologous red blood cells during surgery to conserve donor blood supplies. This technology revolutionized perioperative care by enabling rapid recovery of up to 50% of a patient's lost , thereby lowering transfusion-related risks such as incompatibility and at a time when blood safety concerns were intensifying. Despite initial challenges in gaining adoption due to surgical skepticism and regulatory hurdles, the system's reliability—processing blood via continuous —quickly gained traction, supported by Haemonetics' commitment to rigorous R&D funded through private sources. The Cell Saver not only boosted the company's hospital market presence but also underscored its role in advancing practices. Haemonetics further expanded its portfolio in 1984 with the PCS (Plasma Collection System), an automated apheresis device that accelerated plasma donation by separating and returning non-plasma components to donors in under 40 minutes, yielding higher-quality source plasma for fractionation. This innovation built on the company's disposable product line and addressed inefficiencies in manual plasma phlebotomy, which had limited supply for pharmaceutical uses like clotting factors. Early challenges persisted, including sustaining R&D amid private funding limitations and adapting to evolving standards for blood safety, yet the PCS marked Haemonetics' strategic entry into the growing plasma industry, enhancing donor throughput and product integrity through precise centrifugal control.

Growth and Key Milestones

Haemonetics Corporation went public for the first time in 1979 through an over-the-counter . The company was later acquired by American Hospital Supply Corporation in 1983 and integrated into in 1985 before being taken private. It went public again in May 1991 through an on the (NYSE: HAE), marking its independence and providing capital for expansion in blood management technologies during the , enabling the company to broaden its product portfolio beyond early innovations like autologous blood recovery systems. In the , Haemonetics entered the software solutions market, acquiring assets that enhanced donor management and blood center operations, such as the 2010 purchase of Global Med Technologies, Inc., which broadened its blood management software offerings. The company relocated its global headquarters from , to in 2019, occupying a 62,000-square-foot facility at 125 Summer Street to support collaborative innovation and talent acquisition in a major biotech hub. Key acquisitions drove significant growth in the 2010s and 2020s. In 2012, Haemonetics acquired Pall Corporation's transfusion medicine business for approximately $550 million, integrating advanced blood collection, filtration, and processing technologies. This was followed by the 2021 acquisition of Cardiva Medical for $475 million upfront plus up to $35 million in contingent payments, adding vascular closure devices to its hospital portfolio. In 2023, the company purchased OpSens Inc. for about $255 million USD (CAD $345 million), incorporating fiber optic pressure sensors for cardiovascular applications. Most recently, in 2024, Haemonetics acquired Attune Medical for $160 million upfront plus contingent consideration based on future sales, expanding into esophageal cooling and patient temperature management technologies. To streamline operations, Haemonetics divested its assets to GVS S.p.A. in January 2025 for up to $67.1 million ($44.6 million upfront plus up to $22.5 million in earn-outs), allowing sharper focus on high-growth plasma and segments. Post-2020, the company shifted strategically toward interventional technologies and plasma collection, evidenced by targeted acquisitions and investments in amid global disruptions like vendor interruptions and trade volatility. These efforts contributed to revenue surpassing $1.2 billion, reaching $1.36 billion in fiscal year 2025 ending March 29, 2025.

Products and Services

Plasma Collection Systems

Haemonetics' Plasma Collection Systems are designed for automated in plasma centers, enabling the safe and efficient collection of source plasma from donors. The company's offerings include the PCS2 Plasma Collection System and the newer NexSys PCS system. The PCS2 is a compact, lightweight automated cell separator that uses to separate plasma from while returning other components to the donor. Launched originally in 1984 as the PCS and evolved into the PCS2, this system supports multiple protocols for collecting suitable for source plasma, , or plasma with leukocytes. The NexSys PCS, introduced in the late as the next-generation device, builds on the PCS2 legacy with advanced features including bi-directional connectivity to donor management software, a large interface, automated procedure programming, and technologies like for personalized plasma yield optimization, delivering on average 9-12% additional plasma per donation. It supports higher efficiency and donor comfort while maintaining safety standards. The systems rely on single-use disposable kits to maintain sterility and ensure high-quality plasma output for into therapies. These kits, such as the LN6002 sterile disposable sets, include components like filters, tubing, and anticoagulants (typically citrate-based) that prevent clotting and during the collection . By using closed, single-use disposables, Haemonetics' systems minimize risks and comply with regulatory standards for biopharmaceutical manufacturing. Haemonetics holds a dominant position in the plasma collection industry, with over 70% global market share in plasma collection devices, powering the for production of plasma-derived therapies such as immunoglobulins for treatment and for blood and liver disorders. These systems facilitate the collection of high volumes of source plasma to meet rising global demand for these life-saving biologics. Innovations in the PCS2 and NexSys PCS include advanced optical sensors for precise monitoring, redundant air detectors, donor-line pressure monitors, and fluid sensors to enhance donor safety and prevent adverse events like or overdraw. Additionally, integration with software like NexLynk DMS enables remote data management and optimized collection protocols, allowing volumes up to 800-900 mL per session based on donor such as BMI and . The plasma segment represents a significant driver for Haemonetics, accounting for 39.3% of in fiscal 2025, driven by disposables and device sales to plasma centers. Amid increasing demand for biologics, the company projects 7-10% in this segment for fiscal 2026, excluding impacts from prior customer transitions.

Hospital Blood Management Solutions

Haemonetics offers a range of devices and systems designed to support blood conservation and in environments, with a focus on surgical and interventional procedures to optimize patient blood use and minimize reliance on donor transfusions. These solutions include systems, vascular closure devices, fiber optic sensors for procedural guidance, and enteral access tools, all aimed at enhancing safety and efficiency in operating rooms and intensive care units. A cornerstone product is the Cell Saver Elite+, an system that recovers and washes a patient's own cells during , enabling reinfusion to reduce the need for allogeneic transfusions. This device features an intuitive interface and disposable sets for efficient processing, supporting medium- to high--loss procedures such as cardiac, orthopedic, and trauma . By salvaging and returning up to 70% of a patient's lost cells, it helps avoid risks associated with donor , including infections and immune reactions. Through the acquisition of Cardiva Medical, Haemonetics expanded its portfolio with the VASCADE vascular closure system, which provides extravascular for femoral arterial and venous access sites following and procedures. The system uses a bioabsorbable patch and collapsible disc technology to achieve rapid closure, reducing time to compared to manual compression and enabling earlier ambulation. Clinical trials have demonstrated zero major complications in randomized evaluations, making it a safer alternative for post-procedure site management. The OpSens acquisition introduced fiber optic sensor technology, exemplified by the OptoWire guidewire, which integrates real-time pressure monitoring into percutaneous coronary interventions (PCI). This second-generation device combines PCI wire performance with accurate (FFR) measurements, featuring low drift for reliable guidance throughout the procedure and supporting informed decisions on placement. It facilitates precise assessment of coronary lesions, potentially improving long-term patient outcomes by optimizing strategies. Following the Attune Medical acquisition, Haemonetics incorporated enteral access devices such as the ENvue tracheobronchial airway assessment tool, which aids in safe placement and monitoring for critically ill patients in ICU settings. The ENvue system uses integrated visualization to confirm proper positioning, reducing risks of misplacement into the lungs or during enteral delivery. This tool supports proactive airway management, minimizing complications like in vulnerable populations. These solutions collectively contribute to reduced transfusion risks by promoting patient-specific blood recovery and precise procedural control, while delivering cost savings through decreased allogeneic blood product usage—studies indicate up to 30% reductions in blood use and associated expenses in implemented programs. Enhanced outcomes include shorter hospital stays and lower complication rates in operating and ICU environments. The hospital segment, encompassing these technologies, saw a 24% revenue increase in fiscal 2025, driven by rising procedural volumes in and surgery.

Blood Bank Technologies

Haemonetics' blood bank technologies provide specialized solutions for , enabling the efficient collection, processing, and preparation of and its components, including platelets, plasma, and red blood cells. These systems prioritize blood safety by incorporating features like leukoreduction to minimize contamination, which can reduce transfusion-related complications such as febrile reactions and alloimmunization. Historically, the company's offerings supported the full spectrum of upstream operations, from donor collection to component separation and quality enhancement, aligning with regulatory requirements for . Key products in this area included automated systems for whole blood collection and separation, such as the Leukotrap filtration systems, which facilitated pre-storage leukoreduction of red blood cells, platelets, and plasma in a closed environment to maintain sterility and component integrity. These systems allowed blood centers to process one unit of into leukoreduced components, improving overall product quality by achieving low residual leukocyte levels—typically less than 5 × 10^6 per unit—while preserving viable cell counts. Legacy processors, including those for component production like the ACP series precursors, further enabled the isolation of high-purity platelets and red cells from donations. In December 2024, Haemonetics divested its entire portfolio of collection, processing, and filtration assets to GVS S.p.A., marking a strategic shift away from traditional operations. This transaction, completed in January 2025, included technologies like the Leukotrap systems and related manufacturing capabilities, resulting in scaled-back emphasis on whole blood-specific tools. Post-divestiture, Haemonetics' blood bank focus has shifted to advanced and cell processing solutions that directly yield components without relying on separation. The MCS®+ 9000 system automates the collection of platelets, plasma, and red blood cells, supporting single- or multi-component donations to meet variable demand and optimize donor utilization. This platform achieves collection efficiencies around 56-66%, depending on donor parameters, while integrating options for in-line leukoreduction to ensure component purity. Complementing this, the ACP® 215 Automated Cell Processor handles post-collection processing of red blood cells, washing away plasma proteins, microaggregates, and cytokines in a fully automated, to mitigate allergic reactions and extend usability. These technologies aid blood centers in inventory management by enabling precise component allocation, integrated testing for pathogens and compatibility, and streamlined distribution to hospitals, all while ensuring compliance with AABB standards for blood banking practices. For instance, the closed-system design of the ACP® 215 supports extended post-thaw storage of frozen red blood cells up to 14 days in additive solutions like AS-3, compared to the standard 24-hour limit for open-system deglycerolization, thereby reducing waste and enhancing supply chain flexibility. The impact of these solutions lies in their ability to boost component recovery and quality, such as achieving platelet yields of 3.6–3.8 × 10^11 per procedure on the MCS®+ , which supports higher transfusion and minimizes donor return frequency. By facilitating leukoreduction and automated processing, Haemonetics' technologies contribute to waste reduction in supply chains, with studies showing decreased bacterial risks and improved post-storage cell viability. Overall, they enable centers to maintain a reliable, safe supply amid fluctuating demands.

Software and Data Solutions

Haemonetics offers the BloodTrack suite as a core component of its software solutions for blood inventory management in settings. This modular platform enables comprehensive tracking of blood products from vein-to-vein, ensuring full from storage through transfusion at the point of care. It incorporates RFID and technologies to facilitate secure and efficient handling, reducing manual errors and optimizing the . In plasma and blood centers, Haemonetics provides donor management software such as NexLynk DMS, which automates recruitment, eligibility screening, and compliance processes. NexLynk DMS streamlines donor questionnaires, queue management, and payment processing while integrating bidirectionally with systems to minimize procedural errors like overdraws or underdraws. Complementing this, Donor360 engages donors through tools, enhancing retention and frequency of donations. These tools support regulatory adherence by codifying standard operating procedures (SOPs) and generating reports for . Haemonetics' analytics platforms deliver actionable insights into blood product usage, waste reduction, and . Within the BloodTrack suite, the Enquiry module offers real-time visibility for clinicians, while SafeTrace Tx includes interactive web-based dashboards that transform data into operational intelligence for blood banks. For plasma operations, NexLynk DMS provides reporting on production, supplies, and equipment performance to identify efficiency opportunities and predict collection needs. These solutions apply across plasma collection and transfusion segments to support data-driven decision-making. The software integrates seamlessly with major hospital information systems, including Epic and Cerner, to enable bidirectional data exchange and streamline workflows from to bedside. This compatibility ensures end-to-end traceability without disrupting existing (EHR) environments. Haemonetics' solutions enhance by 20-30% in tracking and administration tasks, support FDA 21 CFR Part 11 compliance for electronic and signatures, and allow remote monitoring of storage to maintain safety and accessibility.

Corporate Structure

Leadership Team

The leadership team at Haemonetics Corporation, as of November 2025, is led by President and Chief Executive Officer Christopher Simon, who has held the position since May 2016. Simon brings extensive experience in the industry, having previously served as a senior partner at , where he led the global medical products practice and advised on strategic growth in healthcare technologies. Under his tenure, Haemonetics has pursued expansions into interventional technologies, such as vascular closure systems, to diversify beyond traditional blood management solutions. Executive Vice President and James C. D'Arecca joined Haemonetics in April 2022, following roles as at TherapeuticsMD and senior finance positions at Companies. D'Arecca oversees financial operations, including budgeting, , and capital allocation to support the company's growth in plasma and hospital segments. In April 2025, Frank W. Chan, Ph.D., was appointed Executive Vice President and , effective April 7. Chan, with over 25 years in medical devices, previously served as President of Medtronic's and Monitoring unit, bringing expertise in operations, , and ; he now directs efforts alongside operational efficiencies. Other key executives include Senior Vice President and Laurie , appointed in August 2021, who manages talent acquisition, employee development, and to foster . The head of reports to Chan, emphasizing advancements in blood collection and processing technologies, while global sales are led by Executive Vice President and Roy Galvin, focusing on in plasma and solutions. Recent leadership changes include the March 2025 promotion of Roy Galvin from President of Global Plasma and Blood Center to Chief Commercial Officer, aimed at accelerating commercial strategies and growth initiatives. Under Simon's leadership, the team has overseen acquisitions that bolstered the interventional portfolio, enhancing synergies between plasma collection and hospital blood management. Overall, Haemonetics' executive team prioritizes cross-functional collaboration to integrate plasma and segments, driving operational synergies and in medical technologies.

Global Operations

Haemonetics maintains a global presence, and selling its products in approximately 95 countries through direct sales operations and independent distributors in about 90 countries. In 2025, the company generated 74.3% of its net revenues of $1.36 billion from the , with the remaining 25.7% from international markets, including at 12.9%, at 4.6%, the rest of at 6.8%, and other regions at 1.4%. This distribution underscores Haemonetics' strong North American base while highlighting growth in key international regions such as and . The company's principal manufacturing facilities are located in Pennsylvania, United States; Tijuana, Mexico (with adjusted operations following divestiture of certain assets); Quebec, Canada; and Penang, Malaysia, focusing on the production of consumables, capital equipment, and related components. These sites support the assembly and production of plasma collection systems, hospital blood management solutions, and blood bank technologies. The acquisition of OpSens Inc. in December 2023 expanded manufacturing and R&D capabilities in Quebec, Canada, enhancing the company's cardiovascular device portfolio. Additional sourcing for components occurs in Japan, Singapore, Thailand, Indonesia, and the Philippines, while liquid solutions are obtained from Europe. Haemonetics employs a vertically integrated for the production of disposables and devices, sourcing key materials globally to ensure efficiency and . Following disruptions from the , the company has prioritized supply chain resilience through diversified sourcing, quality audits of direct suppliers, and investments in operational continuity, enabling it to maintain product availability across its international network. This approach includes annual audits targeting approximately one-third of suppliers via in-person or virtual methods to uphold ethical and operational standards. Regulatory compliance is integral to Haemonetics' global operations, with products certified under the CE Mark for sale in the and adapted to meet local standards for plasma collection in various regions. The company adheres to international regulations, including those from the U.S. , and ensures compliance with foreign currency and jurisdictional requirements in markets like , where exposure to the influences operations. As of March 29, 2025, Haemonetics employed the of 3,023 persons worldwide, with approximately 78% based in and 22% distributed across 19 other countries to support localized , sales, and . This workforce distribution facilitates tailored adaptations to regional needs, such as customized plasma collection protocols and integration solutions.

Financial Performance

Revenue Segments

Haemonetics Corporation's revenue is segmented into three primary business units: Plasma, , and Blood Center, which collectively encompass its plasma collection systems, hospital blood management solutions, blood bank technologies, and software and data solutions. For 2025, ending March 31, 2025, the company reported total net revenue of $1.36 billion, marking a 4.0% increase year-over-year on a reported basis and 4.3% in constant currency, driven by strong performance in the Hospital segment offsetting declines in the other areas. The Plasma segment, the company's largest by historical contribution but second in fiscal 2025, generated $535.4 million in , representing 39.4% of and a 6.0% decline year-over-year, primarily due to lower volumes in from the transition of a major customer, CSL Plasma. This segment's stems mainly from disposables and equipment sales to automated plasma collection centers, fueled by ongoing demand for source plasma used in biologics manufacturing, with technologies like NexSys PCS® utilizing YES® and Persona® features enhancing donor management and collection efficiency. Despite the fiscal 2025 dip, the segment showed resilience through U.S. regulatory advantages and share gains, with guidance for fiscal 2026 projecting a 4-7% reported decline but 14-17% excluding CSL impacts, anticipating renewed expansion from market recovery and . The Hospital segment led revenue growth in fiscal 2025, contributing $564.3 million or 41.4% of total, with a robust 23.7% year-over-year increase (24.0% in constant currency), propelled by higher procedure volumes and acquisitions such as Attune Medical and OpSens Medical. Revenue here is derived from interventional devices like the VASCADE® Vascular Closure System and blood management technologies including TEG® hemostasis analyzers, addressing surgical and transfusion needs in hospitals. Key drivers include rising surgical volumes and adoption of patient blood management solutions, with fiscal 2026 guidance forecasting 4-7% growth in both reported and organic terms, supported by integration of acquired technologies and expanding interventional portfolios. The Blood Center segment, encompassing technologies and software solutions, accounted for $261.1 million or 19.2% of total revenue in fiscal 2025, reflecting a 7.8% year-over-year decrease (6.7% in constant currency), largely attributable to the divestiture of the product line and a $6.8 million charge. This area benefits from steady demand for efficiency tools in plasma and platelet processing, as well as digital adoption of software for and donor , though the exit reduced its share; software subcomponents continue to exhibit 5-10% growth trends from broader healthcare . Fiscal 2026 outlook anticipates a 17-19% reported decline due to the divestiture's lingering effects, with flat to slightly negative organic performance, offset by focus on core and software enhancements.
SegmentFY2025 Revenue ($M)% of TotalYoY Growth (Reported)
Plasma535.439.4%-6.0%
564.341.4%+23.7%
Blood Center261.119.2%-7.8%
Total1,360.8100%+4.0%
In the first quarter of fiscal 2026, fell 4.4% year-over-year to $321.4 million, reflecting ongoing plasma headwinds from the CSL transition, though total organic growth was positive at 0.5% and 12.9% excluding CSL impacts, with revenues rising 4.2% to $139.7 million amid procedural demand.

Stock and Market Position

Haemonetics Corporation has been publicly traded on the under the ticker symbol HAE since its re-initial public offering on May 9, 1991, following its first public ownership beginning in 1979. As of November 13, 2025, the company's stands at approximately $3.42 billion. In 2025, Haemonetics' stock has shown volatility amid sector challenges in , with a year-to-date return of approximately -6% through mid-November 2025, reflecting broader headwinds such as fluctuating plasma collection volumes. However, shares rallied more than 48% from November 6 to November 13, 2025, following the release of stronger-than-expected second-quarter fiscal 2026 earnings, which highlighted resilient organic revenue growth of -1.8% (or +9.4% excluding CSL) and an upbeat outlook for the plasma segment driven by recovering market demand and product enhancements like the Vascade system. This recent surge was further supported by the company's announcement of progress under its $500 million program, authorized by the in April 2025 to offset dilution from employee equity grants and signal confidence in long-term value. As of November 18, 2025, the is approximately $3.44 billion. Haemonetics maintains a leading competitive position in key markets, holding over 70% share in the plasma collection device segment, where it competes primarily with BCT's automated systems. In hospital management, particularly technologies, the company commands approximately 40% market share, positioning it strongly against rivals like PLC in intraoperative recovery solutions. These advantages stem from Haemonetics' focus on innovative disposables and software integration, enabling efficient plasma yield and transfusion optimization. Analysts maintain a positive outlook on Haemonetics, with a consensus rating of "Moderate Buy" from 12 firms as of November 2025, including eight buy recommendations, and an average 12-month price target of $83.00, suggesting potential upside of about 15% from recent levels and indicating undervaluation relative to growth. The company projects of $1.5 billion by 2028, implying a (CAGR) of 2.6% from current levels, supported by plasma expansion and hospital segment momentum. Key risks include heavy reliance on sustained plasma demand for production, which could be disrupted by economic pressures on collection centers, and evolving regulatory changes in , such as recent FDA guidance on plasma donor eligibility that may impact supply volumes.

References

  1. https://haemonetics.gcs-web.com/static-files/c3810e5b-ce8f-46e3-8e76-c66ff4145609
  2. https://finance.yahoo.com/quote/HAE/profile/
  3. https://www.haemonetics.com/about-us
  4. https://www.nytimes.com/2003/08/18/us/jack-latham-95-developed-devices-to-aid-blood-transfer.html
  5. https://matrixbcg.com/blogs/brief-history/haemonetics
  6. https://www.encyclopedia.com/books/politics-and-business-magazines/haemonetics-corporation
  7. https://hospital.haemonetics.com/
  8. https://www.haemonetics.com/about-us/purpose-mission-and-values
  9. https://www.haemonetics.com/contact-support
  10. https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-opens-new-corporate-headquarters-downtown-boston
  11. https://www.haemonetics.com/about-us/corporate-responsibility/canadian-forced-and-child-labour-transparency-statement
  12. https://www.tradingview.com/news/tradingview:a4a600fe9db5c:0-haemonetics-corp-sec-10-k-report/
  13. https://www.haemonetics.com/-/media/files/haemonetics-code-of-conduct.pdf
  14. https://www.haemonetics.com/security-updates
  15. https://www.haemonetics.com/-/media/files/qmpolicy0001enaa.pdf
  16. https://www.haemonetics.com/-/media/files/corporate-responsibility/haemonetics-2022-corporate-responsibility-report-_final_%2874796%2C-d-%2C1%29.pdf
  17. https://www.haemonetics.com/about-us/corporate-responsibility
  18. https://www.fundinguniverse.com/company-histories/haemonetics-corporation-history/
  19. https://www.annualreports.com/HostedData/AnnualReportArchive/h/NYSE_HAE_2011.pdf
  20. https://onlinelibrary.wiley.com/doi/10.1111/vox.12527
  21. https://pubmed.ncbi.nlm.nih.gov/3397375/
  22. https://plasma.haemonetics.com/device-solutions/pcs2
  23. https://plasma.haemonetics.com/device-solutions/nexsys-pcs
  24. https://www.prnewswire.com/news-releases/haemonetics-receives-fda-clearance-for-enhancements-to-nexsys-pcs-plasma-collection-system-301857879.html
  25. https://koalagains.com/stocks/NYSE/HAE
  26. https://plasma.haemonetics.com/
  27. https://seekingalpha.com/news/4518312-haemonetics-raises-2026-guidance-projects-7-percent-10-percent-organic-growth-ex-csl-amid
  28. https://hospital.haemonetics.com/cell-salvage
  29. https://hospital.haemonetics.com/sensor-guided-technology
  30. https://hospital.haemonetics.com/vascular-closure/vascade
  31. https://hospital.haemonetics.com/cell-salvage/cell-saver-elite-plus
  32. https://hospital.haemonetics.com/-/media/files/hospital/cell-saver/col-copy-001739-us%28aa%29_cellsaveric.pdf
  33. https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-acquire-cardiva-medical-inc-expand-hospital
  34. https://hospital.haemonetics.com/sensor-guided-technology/optowire
  35. https://hospital.haemonetics.com/-/media/files/hospital/col-copy-002081_aa_optowire_iii_brochure-%281%29.pdf
  36. https://opsensmedical.com/2021/04/01/optowire-clinical-and-health/
  37. https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-corporation-completes-acquisition-attune-medical
  38. https://www.clinicaltrials.gov/study/NCT03505593
  39. https://www.mdedge.com/ehospitalistnews/article/110757/general-surgery/blood-management-strategy-leads-cost-savings-less
  40. https://bloodcenter.haemonetics.com/-/media/files/blood-center/products/rc-pl-system-colcopy000530usad.pdf
  41. https://www.haemonetics.com/-/media/files/cell-saver-manuals/120745-ie-aa-pdf.pdf
  42. https://www.prnewswire.com/news-releases/haemonetics-announces-sale-of-whole-blood-assets-to-gvs-spa-302320478.html
  43. https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-completes-sale-whole-blood-assets-gvs-spa
  44. https://bloodcenter.haemonetics.com/apheresis
  45. https://bloodcenter.haemonetics.com/cell-processing
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC4680787/
  47. https://www.sciencedirect.com/science/article/abs/pii/S0377123725002126
  48. https://corescholar.libraries.wright.edu/cgi/viewcontent.cgi?article=1105&context=mph
  49. https://onlinelibrary.wiley.com/doi/10.1111/trf.16747
  50. https://www.ovid.com/journals/joca/pdf/10.1002/jca.70054~a-prospective-comparative-study-of-highyield
  51. https://bloodcenter.haemonetics.com/-/media/files/blood-center/products/col-copy-001726-us%28aa%29_final-lo-res_spreads.pdf
  52. https://hospital.haemonetics.com/transfusion-management/bloodtrack
  53. https://plasma.haemonetics.com/software-solutions/nexlynk-dms
  54. https://plasma.haemonetics.com/-/media/files/plasma/nexlynk_dms-brochure.pdf
  55. https://hospital.haemonetics.com/-/media/files/hospital/transfusion-management/safetrace-tx-interoperability-tech-sheetcol-copy-001611-gb%28aa%29.pdf
  56. https://haemonetics.gcs-web.com/board-member/chris-simon
  57. https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-appoints-james-darecca-chief-financial-officer
  58. https://www.prnewswire.com/news-releases/haemonetics-announces-executive-leadership-updates-302390394.html
  59. https://councils.forbes.com/profile/Frank-Chan-Chief-Operating-Officer-Haemonetics-Haemonetics/126dfffa-24a7-4db1-9623-4e77996a946e
  60. https://theorg.com/org/haemonetics/org-chart/laurie-miller
  61. https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-announces-executive-leadership-updates
  62. https://www.prnewswire.com/news-releases/haemonetics-corporation-completes-acquisition-of-opsens-inc-302012273.html
  63. https://www.haemonetics.com/about-us/corporate-responsibility/modern-slavery-act-transparency-statement
  64. https://www.prnewswire.com/news-releases/haemonetics-announces-ce-mark-certification-for-the-savvywire-pre-shaped-pressure-guidewire-302209092.html
  65. https://haemonetics.gcs-web.com/static-files/6b14ac73-0586-4e05-be94-77ec26069612
  66. https://www.nasdaq.com/articles/haemonetics-hae-q1-revenue-falls-4
  67. https://haemonetics.gcs-web.com/static-files/078498e0-b75c-4cd4-94fb-93730b3b1c70
  68. https://stockanalysis.com/stocks/hae/
  69. https://stockanalysis.com/stocks/hae/market-cap/
  70. https://www.trefis.com/stock/hae/articles/582589/10-day-rally-sends-haemonetics-stock-up-48/2025-11-13
  71. https://seekingalpha.com/article/4840268-haemonetics-is-still-undervalued-even-after-the-rally
  72. https://haemonetics.gcs-web.com/static-files/89295437-34ea-473c-ae6e-409a07328239
  73. https://companiesmarketcap.com/haemonetics/marketcap/
  74. https://www.linkedin.com/pulse/top-plasma-extractors-companies-how-compare-them-2025-kxqvf/
  75. https://www.congruencemarketinsights.com/report/autotransfusion-devices-market
  76. https://www.marketbeat.com/stocks/nyse/hae/news/
  77. https://www.marketwatch.com/investing/stock/hae/analystestimates
  78. https://finance.yahoo.com/news/haemonetics-hae-rising-profits-offset-042504162.html
  79. https://simplywall.st/stocks/us/healthcare/nyse-hae/haemonetics/news/what-the-recent-fda-plasma-guidance-means-for-haemonetics-in
Add your contribution
Related Hubs
User Avatar
No comments yet.